The PANORAMA (Study of the Efficacy and Safety of Intravitreal Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy) study suggested a dose-dependent effect on DRSS improvement,7 supporting the importance of past anti-VEGF exposures and baseline DR severity. Here, VEGFA is linked to non-proliferative diabetic retinopathy.